CAPLIPOINT Caplin Point Laboratories Q4 FY25 results (Jan–Mar 2025) and concall
Caplin Point Laboratories delivered a strong Q4 and FY25, showcasing robust revenue and profit growth, record-high margins, and significant progress in product approvals and market expansion, particularly in Latin America. While the US growth trajectory for Caplin Steriles is slower than initially anticipated, management emphasizes sustainable, high-quality growth and strategic long-term investments in API and oncology. The company maintains a strong liquidity position and a debt-free balance sheet, with a focus on operational efficiency and new product launches.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 483 | 493 | 502 |
| EBITDA | 165 | 162 | 168 |
| Net profit | 131 | 140 | 145 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
